|

Breast Cancer Clinical Trials in Charlotte, NC

45 recruiting studies within 50 miles

Phase
Trial Phase Dist.
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine TherapyPhase 3<1 mi
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus PembrolizumabPhase 3<1 mi
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)Phase 3<1 mi
The CDK4/6 Inhibitor Dosing Knowledge (CDK) StudyPhase 3<1 mi
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25Phase 3<1 mi
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)Phase 3<1 mi
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics—<1 mi
National Cancer Institute "Cancer Moonshot Biobank"—<1 mi
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus TrastuzumabPhase 3<1 mi
Self Reported Pain in Women While Undergoing Treatment for Non-metastatic Breast Cancer—<1 mi
A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib StudyPhase 2<1 mi
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast CancerPhase 1/2<1 mi
EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)—<1 mi
Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast CancerPhase 1<1 mi
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)Phase 3<1 mi
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)Phase 3<1 mi
X-ray Psoralen Activated Cancer Therapy in Head and Neck, Breast, Sarcoma and MelanomaPhase 1<1 mi
WATD and Cancer-Related Fatigue: A Study For Patients Undergoing Anti-Cancer Treatment—<1 mi
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast CancerPhase 3<1 mi
Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced CancerPhase 1/2<1 mi
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)Phase 3<1 mi
Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic TherapyN/A<1 mi
A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H MutationPhase 1<1 mi
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid MalignanciesPhase 1/2<1 mi
Comparing Single vs Multiple Dose Radiation for Cancer Patients With Brain Metastasis and Receiving ImmunotherapyN/A<1 mi
First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid TumorsPhase 1<1 mi
A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor MalignanciesPhase 1/213 mi
A Study to Investigate APL-5125 in Adults With Advanced Solid TumorsPhase 1/213 mi
Study of INCB123667 in Subjects With Advanced Solid TumorsPhase 113 mi
A First-in-Human Study of SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid TumorsPhase 113 mi
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid TumorsPhase 1/213 mi
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid TumorsPhase 113 mi
A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4Phase 113 mi
Study of XB010 in Subjects With Solid TumorsPhase 113 mi
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway AlterationsPhase 1/213 mi
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of Azirkitug (ABBV-514) Alone or in Combination With Budigalimab or BevacizumabPhase 113 mi
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory CarcinomasPhase 113 mi
Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN TrialsN/A20 mi
Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast CancerPhase 320 mi
S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast CancerN/A20 mi
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast CancerPhase 320 mi
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation—23 mi
Increasing Germline Genetic Testing for Patients With CancerN/A37 mi
Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer SurvivorsN/A47 mi
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection—47 mi

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.